Hosted on MSN25d
Ascentage Pharma raises $126m in first biotech IPO of 2025China-based biotech Ascentage Pharma has raised $126m in a US initial public offering (IPO), marking the first biotech IPO of 2025. The company sold 7,325,000 American Depositary shares at $17.25 each ...
Ascentage Pharma, a China-based drug developer with global ambitions, now has $126.4 million from a U.S. IPO that will mainly support late-stage clinical development of two medicines that could ...
Shares of Ascentage Pharma Group (AAPG) (OTCPK:AAPGV) (OTCPK:ASPHF), which is backed by Takeda (NYSE:TAK), were trading largely flat Friday following the company's $126M U.S. initial public offering.
Shares of Ascentage Pharma Group International pared earlier losses to rise 0.75% in the Chinese biopharmaceutical company’s US trading debut, after pricing its $126.4 million initial public ...
Takeda-backed Ascentage Pharma Group (AAPG) (OTCPK:ASPHF), (OTCPK:AAPGV) which is developing treatments for blood cancer, has set terms for a $170M U.S. initial public offering. In an SEC filing ...
Its IPO is one of several on tap for the biotech ... plus royalties of 12% to 19% of net sales. Ascentage Pharma’s Rockville hub, totaling 6,520 square feet, is its only U.S. office.
Ascentage Pharma said on Tuesday it was targeting a valuation of $1.75 billion in its initial public offering, becoming the first sizeable Chinese firm to pursue a listing in the U.S. this year.
Investing.com -- Ascentage Pharma's (NASDAQ: AAPG) IPO began trading Friday on the NASDAQ. Shares opened at $17.25 per ADS, in line with the initial public offering (IPO) price of $17.25. The ...
Chinese biotech Ascentage Pharma has taken the first US biotech initial public offering (IPO) of 2025 over the finish line, raising $126 million for its pipeline of small-molecule cancer drugs.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results